drugset / Trial / NCT04783090
MT1013 Clinical TRIAL In Healthy Subject
Phase 1
Completed
40 enrolled
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
WCCT Global · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose administration phase one clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of MT1013 injection in healthy subjects.
Timeline
- Start
- 2021-06-28
- Primary completion
- 2021-12-31
- Completion
- 2022-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT1013 | Peptide | 2.5 mg | — |
| Subject | MT1013 | Peptide | 5 mg | — |
| Subject | MT1013 | Peptide | 10 mg | — |
| Subject | MT1013 | Peptide | 15 mg | — |
| Subject | MT1013 | Peptide | 20 mg | — |
Indications
No indication recorded.